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ABSTRACT
Objective: The present study investigated the possible effect of fenofibrate and gemfibrozil peroxisome proliferator-activated receptor-alpha agonist 
in diabetes-induced acute kidney injury (AKI) in rats.
Methods: Rats were administered streptozotocin (STZ) (50 mg/kg, i.p., single dose) to induce experimental diabetes mellitus. The development of 
diabetic AKI was assessed biochemically and histologically. In addition, the diabetes-induced lipid profile and renal oxidative stress were assessed. 
The single dose of STZ produced diabetes, which induced renal oxidative stress, altered the lipid profile and subsequently produced kidney injuryAKI 
in 7 weeks by increasing serum creatinine, blood urea nitrogen (BUN), proteinuria, and glomerular damage. Treatment with fenofibrate and 
gemfibrozil (30 mg/kg p.o, 7 weeks) normalized the altered lipid profile by decreasing serum cholesterol, triglycerides, and increasing serum high-
density lipoprotein in diabetic rats. Lisinopril (1 mg/kg, p.o., 7 weeks, reference compound) prevents lipid alteration and development of diabetic AKI.
Result: Fenofibrate and gemfibrozil, besides hyperglycemia, significantly prevented the development of diabetic AKI by reducing (serum and tissue) 
oxidative stress, hyperlipidemia, serum BUN, creatinine, and urinary protein. Further, fenofibrate, but not gemfibrozil, considerably reduced renal 
structural and functional abnormalities in diabetic rats. The fenofibrate was more effective in attenuating the diabetes-induced AKI and renal oxidative 
stress as compared to treatment with and gemfibrozil.
Conclusion: The fenofibrate and gemfibrozil treatment markedly prevented the diabetes-induced AKI. In comparison, the fenofibrate is found to be a 
superior approach to attenuate the diabetic AKI than gemfibrozil.
Keywords: Diabetes, Fenofibrate, Gemfibrozil, Nephropathy.
INTRODUCTION
Diabetes is a metabolic disorder characterized by hyperglycemia 
followed by micro- and macro-vascular complications [1]. Diabetic 
nephropathy is an important microvascular complication of diabetes 
and is widely recognized as the most common cause of the end-
stage renal failure. Diabetes mediated acute kidney injury (AKI) is 
one of the leading causes of morbidity and mortality. Hyperglycemia, 
vascular endothelial dysfunction, and hyperlipidemia are considered 
as possible reasons behind the pathogenesis and progression of 
diabetic nephropathy [2]. Hyperglycemia mainly targets the almost 
all the kidney cellular elements such as glomerular endothelial cells, 
mesangial cells, podocytes, and tubular epithelial injury.
Further, the growing glomerulosclerosis, thickening of the glomerular 
basement membrane, glomerular hypertrophy, mesangial cell 
expansion, podocyte loss, renal-cell hypertrophy, and tubulointerstitial 
fibrosis are major pathological changes during the course of diabetic 
nephropathy, which ultimately results in functional consequences, 
including progressive albuminuria, reduction in glomerular filtration 
rate, elevation of arterial blood pressure, and fluid retention [3]. It is 
interesting that recent studies demonstrated numerous pleiotropic 
effects of peroxisome proliferator-activated receptor-alpha (PPAR-α) 
agonist such as fenofibrate and gemfibrozil. Gemfibrozil is well 
known to produce antihyperlipidemic action by activation of PPAR-α. 
In addition to this, upregulation of PPAR-α had an important role in 
affording the protection against experimental acute kidney failure. 
A recent study revealed the mechanism of cardioprotection by 
gemfibrozil by attenuating oxidative stress. Importantly, research 
exhibiting the most pronounced benefits of gemfibrozil in preventing 
vascular events by direct activation and protection of guanylyl cyclase 
(sGC) the key mediator of NO signaling [4]. The gemfibrozil mediated 
activation of guanylyl cyclase may be a rational concept to attenuate 
the oxidative stress and hyperlipidemia. Further, fenofibrate is well 
documented to attenuate diabetes-induced endothelial function 
by upregulating eNOS and by decreasing oxidative stress and 
hyperlipidemia [5]. Further, the nephroprotective role of fenofibrate 
is reported in diabetes by ameliorating oxidative stress and 
hyperlipidemia. Furthermore, fenofibrate has been shown to reduce 
glomerular hypertrophy, mesangial matrix expansion and suppress 
the expression of plasminogen activator inhibitor-1 and transforming 
growth factor-b [5,6]. Therefore, the renovascular protective role of 




The Institutional Animal Ethical Committee approved the experimental 
protocol used in the present study. Age-matched young Wistar rats 
weighing about 200–250 g were employed in the present study. The 
animals were housed in the room maintained at approximately 24±1°C 
temperature and humidity of 55±5% with 12-h light/dark cycle. Free 
access to food (standard chow from Ashirwad Industries, Ropar, India) 
and water was allowed. The animals were acclimatized for at least 
3–4 days before the initiation of the experiment and were observed 
for any sign of disease. The animals were maintained under proper 
conditions until the termination of the experiment. The animals were 
sacrificed after a predetermined period of the treatment as per the 
study design to evaluate various parameters.
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i1.29397
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Experimental protocol
Seven groups were employed in the present study and each group 
comprised 8 animals each. The fenofibrate and gemfibrozil were 
dissolved in 1% w/v of carboxymethylcellulose (CMC) and water, 
respectively.
Drug-treated diabetic group
Group I (normal control)
Rats were maintained on standard food and water, and no treatment 
was given.
Group II (diabetic control)
Rats were administered streptozotocin (STZ) (50 mg/kg, i.p., once) 
dissolved in citrate buffer (pH 4.5).
Group III (fenofibrate per se)
Rats were administered fenofibrate (30 mg/kg p.o.) dissolved in 
1% w/v CMC for 7 weeks.
Group IV (gemfibrozil per se)
Rats were administered gemfibrozil (30 mg/kg p.o.) dissolved in water 
for 7 weeks.
Group V (fenofibrate treated diabetic group)
The diabetic rats after 1 week of STZ administration were treated with 
fenofibrate (30 mg/kg p.o.) for 7 weeks.
Group VI (gemfibrozil treated diabetic group)
The diabetic rats after 1 week of STZ administration were treated with 
gemfibrozil (30 mg/kg p.o.) for 7 weeks.
Group VII (lisinopril treated diabetic group)
The diabetic rats after 1 week of STZ administration were treated with 
lisinopril (1 mg/kg p.o.) for 7 weeks (Fig. 1).
Drugs and chemicals
STZ and acetylcholine hydrochloride were obtained from Sigma-Aldrich 
Ltd, St. Louis, USA. 1,1,3,3 tetra methoxypropane and carboxymethyl 
cellulose were purchased from V. K. Chemicals and Instruments, 
Ambala, India. The fenofibrate and gemfibrozil were obtained from 
Ranbaxy Laboratory Ltd., Gurgaon, India. Lisinopril was obtained from 
Dr. Reddy’s Laboratory Ltd., Hyderabad, India. All other chemicals used 
in the present study were of analytical grade.
Estimation of serum glucose
At the end of the experimental protocol, the blood samples were 
collected, and serum was separated after allowing to clot followed by 
centrifugation. The glucose concentration was estimated by glucose 
oxidase-peroxidase GOD-POD method using the commercially available 
kit (Bio Lab Diagnostics India Private Limited) [5].
Assessment of lipid profile
Estimation of serum total cholesterol
The total cholesterol was estimated by cholesterol oxidase peroxidase 
CHOD-POD method using the commercially available kit (Bio Lab 
Diagnostics India Private Limited) [5,6].
Estimation of serum triglycerides
The serum triglyceride was estimated by GOD-POD method using 
the commercially available kit (Bio Lab Diagnostics India Private 
Limited) [5,6].
Estimation of high-density lipoprotein (HDL)
The HDL was estimated by CHOD-POD method using the commercially 
available kit (Bio Lab Diagnostics India Private Limited) [5,6].
Assessment of oxidative stress
The oxidative stress in serum samples was assessed by estimating 




1 ml of 20% trichloroacetic acid was added to 100 µL of serum 
and 1% TBA reagent (1.0 mL) which were mixed and incubated at 
100°C for 30 min. After cooling on ice, samples were centrifuged at 
1000 g for 20 min. Serum concentration of TBARS was measured 
spectrophotometrically at 532 nm. A standard curve using 1, 1, 3, 
3-tertramethoxyopropane (1–10 µM) was plotted to calculate the 
concentration of TBARS [5,6].
Tissue
The kidney was excised and washed with ice-cold isotonic saline and 
weighed. The kidney weight to body weight ratio was calculated. The 
kidney was then minced, and a homogenate (10% w/v) was prepared 
in chilled 1.15% KCl. The homogenate was used for the estimation of 
renal TBARS and glutathione (GSH).
The renal TBARS, an index of lipid peroxidation, were estimated 
according to the method described earlier. The reaction mixture was 
prepared by mixing 0.2 mL of tissue homogenate, 0.2 mL of 8.1% sodium 
dodecyl sulfate, 1.5 mL of 20% acetic acid solution (adjusted to pH 3.5 
with NaOH), and 1.5 mL of 0.8% aqueous solution of TBA. The reaction 
mixture was made up to 4.0 ml with distilled water and then incubated 
at 95°C for 60-min. After cooling in tap water, 1.0 mL of distilled water 
and 5.0 mL of the mixture of n-butanol and pyridine (15:1 v/v) were 
added to reaction mixture and shaken vigorously using vortex shaker. 
The test tubes were centrifuged at 12,520 g (radius of the rotor was 
7 cm) for 10-min (REMI Cooling Centrifuge, India). The absorbance 
of the developed pink color was measured spectrophotometrically at 
532 nm. The standard curve using 1, 1, 3, 3-tertramethoxyopropane 
(1–10 nM) was plotted to calculate the concentration of TBARS, and the 
results were expressed as nM/g wet weight of renal tissue [7].
Estimation of reduced GSH
The renal GSH level was estimated using the methods described by 
Ellman. Ellman’s reagent (5,5’-dithiobis-(2-nitrobenzoic acid) [DTNB]) 
is a chemical used for measuring the amount of thiol group. Thiols 
react with this compound, cleaving the disulfide bond to give 2-nitro-
5-thiobenzoate (NTB-), which ionizes to the NTB2- dianion in water at 
neutral and alkaline pH. This NTB2- ion has a yellow color. The NTB2- is 
quantified in a spectrophotometer by measuring the absorbance at 
412 nm.
The renal homogenate of the rat was mixed with 10% w/v 
trichloroacetic acid in 1:1 ratio and centrifuged at 4°C for 10-min 
at 1957 g. The supernatant (0.5 mL) was mixed with 2 mL of 0.3 M 
disodium hydrogen phosphate buffer (pH 8.4) and 0.4 mL of distilled 
Fig. 1: Study design intervention study on diabetic nephropathy
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water. Then, 0.25 mL of 0.001 M freshly prepared DTNB (dissolved in 
1% w/v sodium citrate) was added to the reaction mixture, and then 
incubated for 10-min. The absorbance of the yellow colored complex 
was noted spectrophotometrically at 412 nm. A standard curve was 
plotted using the reduced form of GSH (0.1–1 mM), and the results were 
expressed as mM/g wet weight of renal tissue [7].
Assessment of AKI
The serum creatinine concentration was estimated by the alkaline 
picrate kinetic method using the commercially available kit (Span 
Diagnostics Ltd., India).
The blood urea was estimated by a method using the commercially 
available kit (Span Diagnostics Ltd., India).
The proteinuria was estimated by pyrogallol red method using the 
commercially available kit (Span Diagnostics Ltd., India) [5-7].
Histopathological study
The early diabetic changes in glomeruli were assessed 
histopathologically. The kidneys were excised and immediately 
immersed in 10% formalin. The kidney was dehydrated in graded 
concentrations of alcohol, immersed in xylene and then embedded in 
paraffin. From the paraffin blocks, sections of 5-µm thickness were 
made and stained with hematoxylin and eosin to assess pathological 
changes in glomeruli using light microscopy (×400) [5,6].
Statistical analysis
All values were expressed as mean ± S.E.M. The data for serum/tissue 
levels of TBARS, serum creatinine, blood urea and proteinuria, serum 
glucose, and lipid profile were statistically analyzed using one-way 
analysis of variance followed by Tukey’s multiple comparison tests. 
p<0.05 was considered to be statistically significant.
RESULT
Pharmacological account of drug in diabetic model
The administration of fenofibrate (30 mg/kg, p.o., 7 weeks) or 
gemfibrozil (30 mg/kg, p.o., 7 weeks) or lisinopril (1 mg/kg, p.o., 
Fig. 2: Effect of fenofibrate, gemfibrozil, and lisinopril on 
plasma glucose in diabetic animals. All results are expressed in 
mean±SEM. ***p<0.001 versus normal control (n=6)
Fig. 3: Effect of fenofibrate, gemfibrozil, and lisinopril on serum 
cholesterol in diabetic animals. All results are expressed in 
mean±SEM. **p<0.01 versus normal control, ##p<0.01, #p<0.05 
versus diabetic control (n=6)
Fig. 4: Effect of fenofibrate, gemfibrozil, and lisinopril on serum 
triglycerides in diabetic animals. All results are expressed in 
mean±SEM. **p<0.01 versus normal control, ##p<0.01, #p<0.05 
versus diabetic control (n=6)
Fig. 5: Effect of fenofibrate, gemfibrozil, and lisinopril on serum 
high-density lipoprotein-cholesterol in diabetic animals. All 
results are expressed in mean±SEM. **p<0.01 versus normal 
control, ##p<0.01, #p<0.05 versus diabetic control (n=6)
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7 weeks) to normal rats did not produce any significant per seceffects 
on various parameters assessed in the present study.
Administration of STZ (50 mg/kg, i.p., single dose) produced 
hyperglycemia after 72 h (serum glucose >180 mg/dL) of injection. After 
7 days of STZ administration, the rats which showed blood glucose level 
>250 mg/dl were selected and were assigned in subsequent groups. 
Fenofibrate, gemfibrozil, and lisinopril were administered to diabetic 
rats after 7 days of injection of STZ, and their treatment was continued 
for 7 weeks. All the parameters were assessed at the end of 7 weeks 
of treatment, i.e., 8 weeks of diabetes induction in all groups. Overall, 
mortality among diabetic animals with or without drug treatments for 
8 weeks was <10%.
Effect of pharmacological interventions on serum glucose
The marked increase in serum concentration of glucose was noted 
in diabetic rats when compared with normal rats. Treatment with 
fenofibrate (30 mg/kg p.o., 7 weeks) or gemfibrozil (30 mg/kg p.o., 
7 weeks) did not affect the serum glucose concentration in diabetic 
rats. However, treatment with lisinopril (1 mg/kg p.o., 7 weeks) slightly 
reduced the glucose level in diabetic rats; the result was not statistically 
significant (Fig. 2).
Effect of pharmacological interventions on lipid profile
The increase in serum concentration of total cholesterol and triglycerides 
and decrease in HDL were noted in diabetic rats when compared with 
normal rats. The treatment with fenofibrate (30 mg/kg p.o., 7 weeks) 
or gemfibrozil (30 mg/kg p.o., 7 weeks) alone significantly attenuated 
diabetes-induced alterations in serum lipids. In addition, treatment 
with lisinopril partially prevented a diabetes-induced increase in total 
cholesterol and triglycerides and decrease in HDL level (Fig. 3-5).
Effect of pharmacological interventions on serum TBARS
The increase in serum TBARS concentration was noted in diabetic rats 
when compared with normal rats. However, treatment with fenofibrate 
(30 mg/kg p.o., 7 weeks) or gemfibrozil (30 mg/kg p.o., 7 weeks) or 
lisinopril (1 mg/kg p.o., 7 weeks) significantly attenuated the diabetes-
induced increase in serum TBARS. In addition, the marked reduction 
in serum TBARS was noted in diabetic rats treated with fenofibrate 
as compared to treatment with gemfibrozil and but not superior than 
lisinopril (Fig. 6).
Effect of pharmacological interventions on renal TBARS and GSH
A marked increase in renal TBARS was noted in diabetic rats as compared 
to normal rats. In addition, a marked decrease in renal GSH was noted in 
diabetic rats as compared to normal rats. The treatment with fenofibrate 
(30 mg/kg p.o., 7 weeks) or gemfibrozil (30 mg/kg p.o., 7 weeks) or 
lisinopril (1 mg/kg p.o., 7 weeks) significantly attenuated the diabetes-
induced increase in renal TBARS and decrease in renal GSH. In addition, 
the marked reduction in renal TBARS and increase in GSH was noted 
in diabetic rats treated with fenofibrate as compared to treatment with 
gemfibrozil and but not superior than lisinopril (Figs. 7 and 8).
Effect of pharmacological interventions on serum creatinine, 
blood urea, and proteinuria
The concentrations of serum creatinine, blood urea, and proteinuria 
were noted to be markedly increased in diabetic rats after 7 weeks 
when compared with normal rats. Treatment with fenofibrate (30 mg/
kg p.o., 7 weeks) or gemfibrozil (30 mg/kg p.o., 7 weeks) or lisinopril 
(1 mg/kg p.o., 7 weeks) attenuated the diabetes-induced increase in 
serum creatinine, blood urea, and proteinuria. In addition, the marked 
reduction in renal serum creatinine, blood urea, and proteinuria was 
noted in diabetic rats treated with fenofibrate as compared to treatment 
with gemfibrozil and but not superior than lisinopril (Figs. 9-11).
Effect of pharmacological interventions on histopathological study 
on kidney
The diabetes was noted to develop pathological changes in the glomeruli 
such as reduced capillary size and extracellular mesangial expansion in 
diabetic rats after 7 weeks when compared with normal rats. Treatment 
with fenofibrate (30 mg/kg p.o., 7 weeks) or gemfibrozil (30 mg/kg 
p.o., 7 weeks) or lisinopril (1 mg/kg p.o., 7 weeks) attenuated diabetes-
induced pathological changes in glomeruli. In addition, the marked 
pathological changes in glomeruli were noted in diabetic rats treated 
with fenofibrate as compared to treatment with gemfibrozil and but not 
superior than lisinopril (Fig. 12a-e).
DISCUSSION
One of the most important functions of the kidney is the filtration 
and excretion of nitrogenous waste products from the blood. The 
measurements of elevated blood urea nitrogen (BUN) and creatinine 
serve as indicators of decreased renal function indicative of the 
decreased clearance of these waste products. AKI is currently defined 
as a rapid decline in the glomerular filtration rate resulting in retention 
of nitrogenous wastes, primarily creatinine and BUN [8]. Concurrently, 
major structural hallmarks of AKI include renal enlargement, mesangial 
cell expansion, tubular injury, and glomerular basement membrane 
thickening [9,10]. There are several reasons for kidney damages, the 
Fig. 6: Effect of fenofibrate, gemfibrozil, and lisinopril on 
serum TBARS in diabetic animals. All results are expressed in 
mean±SEM. ***p<0.001 vs normal control, ##p<0.01; #p<0.05 vs 
diabetic control, @p<0.05 vs gemfibrozil + diabetic animals (n=6)
Fig. 7: Effect of fenofibrate, gemfibrozil, and lisinopril on renal 
thiobarbituric acid reactive substance. All results are expressed 
in mean±SEM. ***p<0.001 versus normal control, ##p<0.01, 
#p<0.05 versus diabetic control, @p<0.05 versus gemfibrozil + 
diabetic animals (n=6)
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primary focus on the potential causes of accounting for the majority of 
nephrology disease as diabetes. There are several mechanisms studied, 
but still, the management of kidney dysfunctions associated with 
diabetes remains obscure.
The animal models for nephropathy share many features which 
are common to human nephropathy and have been delineated by 
targeting proteinuria, glomerulosclerosis, glomerulonephritis, 
glomerular hypertrophy, tubulointerstitial nephritis, tubular necrosis, 
and reduced Gglomerular filtration rate. The number of patients with 
end-stage renal failure requiring dialysis is increasing. Therefore, 
suitable animal models that exhibit progressive renal lesions are 
necessary to identify the mechanisms involved in human nephropathy 
and to develop potential drugs/drug targets for the treatment of renal 
complications. We have used the well-established animal model of 
diabetes using STZ.
At present, angiotensin-converting enzyme (ACE) inhibitors 
such as captopril, lisinopril, and fosinopril are employed to treat 
diabetic nephropathy [11]. However, clinical evidence suggests 
that ACE inhibitors are not sufficient to control the symptoms of 
nephropathy [3,12,13]. The present study has been aimed to explore 
the potential use of PPAR-α to prevent diabetic-induced AKI.
The STZ, a single dose of 50 mg/kg i.p. was employed in the present study 
to induce experimental diabetes in rats. STZ developed hyperglycemia 
within 72 h (serum glucose >180 mg/dL). After 7 days of STZ 
administration, rats which showed the blood glucose level >240 mg/dL 
were selected for the study and are named as diabetic rats. The strong 
association between diabetes and vascular endothelial dysfunction and 
mediated nephropathy is demonstrated in various studies. Frequently, 
the strong correlations between oxidative stress and hyperlipidemia in 
the induction of nephropathy have been reported [5,13]. In diabetes, the 
reactive oxygen species (ROS) one of the main culprits plays a key role 
in the progression of pathophysiological processes of renal diseases. 
Moreover, high glucose-induced ROS generation through activation of 
Fig. 8: Effect of fenofibrate, gemfibrozil, and lisinopril on plasma 
glutathione. All results are expressed in mean±SEM. **p<0.001 
versus normal control, ##p<0.01, #p<0.05 versus diabetic control, 
@p<0.05 versus gemfibrozil + diabetic animals (n=6)
Fig. 9: Effect of fenofibrate, gemfibrozil, and lisinopril on plasma 
blood urea nitrogen. All results are expressed in mean±SEM. 
***p<0.001 versus normal control, ##p<0.01, #p<0.05 versus 
diabetic control, @p<0.05 versus gemfibrozil + diabetic animals 
(n=6)
Fig. 10: Effect of fenofibrate, gemfibrozil, and lisinopril on serum 
creatinine. All results are expressed in mean±SEM. **p<0.001 
versus normal control, ##p<0.01, #p<0.05 versus diabetic control, 
@p<0.05 versus gemfibrozil + diabetic animals (n=6)
Fig. 11: Effect of fenofibrate, gemfibrozil, and lisinopril on urinary 
protein. All results are expressed in mean±SEM. **p<0.001 versus 
normal control, ##p<0.01; #p<0.05 versus diabetic control,  
@p<0.05 versus gemfibrozil + diabetic animals (n=6)
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nicotinamide adenine dinucleotide phosphate oxidase plays a crucial 
role in the induction and progression of diabetic nephropathy [14]. ROS 
has several deleterious effects on cells, including lipid peroxidation, 
oxidation of cell proteins, and damage to DNA [15,16]. These effects can 
result in the loss of plasma membrane and mitochondrial membrane 
integrity, impaired protein function, and inhibition of cell repair and 
proliferation. Several studies support the fact that the oxidative stress 
is an important contributor to the pathogenesis of AKI. In addition, lipid 
peroxidation key phase is initiated by free radicals attack of membrane 
lipids, generating large amounts of reactive products, which have been 
implicated in the pathogenesis of diabetic AKI. The increase in serum 
and tissue TBARS level and the decrease in tissue GSH are regarded as 
an index of development of oxidative stress. Further, the oxidative stress 
has been documented to play a major role in the progression of VED and 
nephropathy [5]. It has been demonstrated that diabetes increases the 
production of ROS, lipid and consequently reduces the synthesis and 
bioavailability of no, which result in AKI [5,17].
In the present study, diabetes has been noted to increase the renal 
TBARS and decrease the GSH levels in the kidney. Thus, it may be 
suggested that diabetes-induced development of oxidative stress may 
develop AKI by damaging renal architecture.
This contention is supported by the results obtained in the present 
study that increases in serum/tissue TBARS reduction and reduction 
in renal GSH and subsequently increase in serum creatinine, blood 
urea, and proteinuria was noted in diabetic rats when treated with 
interventions. However, pharmacological treatment with fenofibrate 
or gemfibrozil prevented diabetes-induced AKI by decreasing serum 
TBARS, increasing renal GSH, decreasing serum creatinine, blood urea, 
and proteinuria and reducing pathological changes in glomeruli.
Thus, it may be suggested that the direct renoprotective potential of 
fenofibrate in preventing diabetic AKI may be due to their antioxidant 
properties on the diabetic kidney. The overall observed beneficial effect 
of fenofibrate or gemfibrozil in preventing the development of diabetic 
AKI may be attributed to their direct renoprotective action, improving 
reversing renal oxidative stress.
In diabetes, the lipid alteration besides hyperglycemia could play key 
roles in the development of AKI of circulating lipids could contribute 
to diabetic animals. Growing evidence supports the fact of significant 
pathologic involvement of diabetes mellitus-associated dyslipidemia 
in the development and progression of diabetic AKI [5-7,18,19]. 
Lipid-mediated injury plays an important role in the pathogenesis of 
diabetic AKI. This contention further, the increase in serum cholesterol, 
triglyceride, and a decrease in HDL are considered as dyslipidemia. 
It suggests the development of diabetes-induced hyperlipidemia. 
Lipoprotein lipase (LPL) located in the vascular endothelium 
involves the breakdown of triglycerides into free fatty acids. LPL gets 
downregulated during insulin deficiency [20]. The hyperlipidemia has 
been noted to play a role in the pathogenesis and progression of VED 
and nephropathy [5,6].
Diabetic kidneys expressed important genes normally found in 
adipocytes and well suggesting a switch of kidney phenotype in favor 
of lipid accumulation in diabetes [21]. In diabetes, insulin inhibits 
the hormone-sensitive lipase production leads to abnormal high 
concentration of serum lipids is mainly due to increase in free fatty acids 
from the peripheral fat deposits and has been noted to be associated with 
the increased expression of transforming growth factor -β1, fibronectin, 
and collagen-IV, which ultimately accounts for glomerulosclerosis 
and tubulointerstitial fibrosis [19,20]. This contention is supported 
by the results obtained in the present study that marked increases 
in serum cholesterol and triglycerides and consequent decrease in 
serum HDL levels were noted in diabetic rats with AKI. Decreased 
expression of PPAR-α has been noted to be associated with the 
progression of diabetic nephropathy through an increase in circulating 
lipids, induction of inflammation, and extracellular matrix formation 
in diabetic mice [22]. In the present study, the increase in serum 
concentration of total cholesterol and triglycerides and a decrease in 
HDL and increase in serum concentration were noted in both diabetic 
rats when compared with normal rats, which indicates both diabetes 
induced-hyperlipidemia. Similar kind of lipid abnormality has been 
noted by previous reports on the same model [23,24].
The diabetes-induced alteration in lipid profile such as 
hypercholesterolemia and hypertriglyceridemia affect the function 
of the glomerulus and produce glomerulosclerosis, which results in 
diabetic nephropathy [24]. Further, insulin has an inhibitory action 
on 3-hydroxy-3-methyl-glutaryl-Co-A (HMG-COA) reductase, a key 
rate-limiting enzyme involved in the synthesis of cholesterol. Hence, 
hypoinsulinemia during diabetes activates HMG-COA reductase 
to stimulate the synthesis of high cholesterol [25]. Moreover, the 
occurrence of proteinuria has been suggested to upregulate HMG-COA 
reductase to produce hypercholesterolemia [26,27]. Accordingly, it may 
be suggested that diabetes-induced hyperlipidemia may develop AKI by 
damaging renal architecture. In the present study, the serum creatinine, 
blood urea, and proteinuria were noted to be increased in diabetic 
rats as compared to normal rats. Moreover, diabetic rats developed 
pathological changes in glomeruli in 7 weeks. These results suggest the 
development of diabetes-induced AKI.
The biochemical alteration and morphological changes in the kidney 
were considered as a primary marker for the induction of AKI. The STZ 
(single dose) used for the induction of diabetes in rats. The renoprotective 
effect of lisinopril has been well reported in basic and clinical 
studies [5,28]. Therefore, lisinopril has been employed as a standard 
drug in the present study. Renoprotection afforded by lisinopril might 
be, in some measure, its glucose-lowering diabetic rats. As dyslipidemia 
is common consequences of renal dysfunction, PPAR-α agonists could 
serve as promising therapeutic agents for controlling the progression 
of diabetic nephropathy. In fact, fenofibrate, a hypolipidemic agent acts 
as a PPAR-α agonist, reduced renal lipotoxicity, inflammation, fibrosis, 
and subsequently prevented the symptoms of diabetic AKI. Further, 
Fig. 12: (a-e) Effect of fenofibrate, gemfibrozil, and lisinopril on 
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gemfibrozil the other PPAR-α agonist noted to be useful to control 
diabetic dyslipidemia and control diabetic nephropathy. Importantly, 
the fenofibrate was noted to be superior in preventing diabetic AKI than 
gemfibrozil. The present work emphasized the rationale for employing 
PPAR-α agonists in the management of diabetic nephropathy.
Structural abstract
CONCLUSION
On the basis of above discussion, diabetes-mediated lipid alteration and 
oxidative stress could play a role in the development of AKI. Fenofibrate 
and gemfibrozil show antihyperlipidemic, antioxidant property, 
and contributed in renoprotection in diabetic rats with AKI. Apart 
from antihyperlipidemic action fenofibrate showed, the significant 
renoprotection action of than gemfibrozil by drastically restructures 
the kidney architect.
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